On November 10, 2025, the FDA announced it was removing the boxed warning language from menopausal hormone therapy products, including the probable-dementia statement that had applied to the whole product class since the early 2000s trials.

The FDA's reasoning was that the original dementia data came from women older than 65, not the typical population that starts hormone therapy, roughly ages 45 to 55, so the warning had been over-extrapolated. This correction is important, but it is not the same thing as new evidence that hormone therapy protects the brain. It resolves an old overreach; it does not create proof of prevention.

What to know about this answer

There is not real scientific disagreement that the original warning was over-extrapolated; the disagreement, such as it is, is over how the change should be interpreted publicly, since both under-reading and over-reading the FDA action are common.

What the research shows, and which source each finding rests on

On November 10, 2025, the FDA announced removal of the boxed warning language on menopausal hormone therapy products, including the probable-dementia statement applied class-wide since the WHIMS era; the endometrial cancer boxed warning stays on systemic estrogen-alone products.

E[1]

The FDA's stated rationale for the dementia item was that the probable-dementia data came from women older than 65, not the population that typically starts hormone therapy (roughly ages 45 to 55).

E[1]

Removing a warning based on the wrong population is not the same as evidence that hormone therapy protects the brain; the action resolves an overextrapolation, it does not create prevention evidence.

E[1]

Where the real disagreement is

Each position is shown with its own sources. A position listed here is not necessarily the accepted view.

the correction is overdue and important, but should not be spun into a protection claim

guideline bodies and skeptical experts, and cautious advocates like Rachel Rubin and Sharon Malone

The extrapolation critique, that the dementia data never applied to vaginal products or to typical hormone therapy starters, is well founded and was ultimately adopted by the FDA itself, but that correction did not generate any new trial evidence that hormone therapy prevents dementia.

E[1]

What would settle it: This is not really an open scientific question; it is a communication and interpretation question, settled by reading the FDA's stated rationale directly rather than headlines about it.

What is really going on here

  1. Does the FDA removing a warning mean there is now proof of benefit, or does it mean an old warning no longer applies?
  2. Was the original warning based on women like me?

Questions for your doctor

  1. How does this regulatory change affect the specific product and regimen you're recommending for me?
  2. Are there other warnings still on my specific product that are still relevant to my situation?
  3. What is the difference, in my case, between a removed warning and a demonstrated benefit?

Questions with no answer yet

Now that the warning has been corrected for the wrong population, will removing it change how often hormone therapy is actually offered to women who could benefit from it for symptoms?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The regulatory action corrects an extrapolation of a finding in women 65 and older to the entire product class. Whether the correction itself changes prescribing behavior or patient uptake has not yet been measured, since the change is recent.

What would test it: A prescribing-pattern study comparing hormone therapy uptake, and specifically vaginal estrogen uptake, before and after the labeling change.

Does correcting an overextrapolated warning tell us anything new about whether hormone therapy protects the brain, or does it only tell us the old warning was misapplied?

Not directly studied yet

No research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.

What is known: The regulatory action explicitly resolves an overextrapolation of the original trial finding; it does not represent new trial data, so it cannot on its own answer whether hormone therapy helps, harms, or does nothing for the brain in the population that actually starts it today.

What would test it: The same dedicated prevention trial called for throughout this topic, since a label change is a regulatory correction, not a scientific finding.

Sources

  1. 1.FDA press announcement on menopausal hormone therapy labeling changes, November 2025Review, opinion or mechanism

The letter grades the type of study behind a claim, not the answer itself.

This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.

You are not imagining it

In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.

Start Free Mapping

Related questions